Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Major stock indexes edged higher Monday to kick off what will be an extraordinarily busy week of news for financial markets.

With more-than-satisfying phase III data in hand, Minneapolis-based Celcuity Inc. is eyeing an NDA submission in the fourth quarter of this year for gedatolisib (geda) in breast cancer. Shares of the ...

Commercial National Financial Corporation (OTCID: CEFC) reported net income for the second quarter of 2025 of $1,607,000 or $0.41 per share compared to second quarter 2024 net income of $1,412,000 or ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $50 from $27 and keeps a Buy rating on the shares. After Celcuity reported ...